Scott Smith, director of project management, CT, Philips Healthcare, describes low-dose CT as nearly a given in the marketplace now. What’s more important is maintaining the speed and quality of the image while using iterative reconstruction to keep the dose low.
Patient and hospital concern over CT dose has created a “perfect storm” for new products in CT, according to Gene Saragness, Philips’ EVP and CEO. Philips iDose4 has had the “fastest uptake I’ve seen in any product.” The Ingenuity CT with iDose4 was originally introduced at last year’s RSNA.
The company will put focus on its latest iDose technology at RSNA 2011.
Scott Smith, director of project management, CT, Philips Healthcare, describes low-dose CT as nearly a given in the marketplace now. What’s more important is maintaining the speed and quality of the image while using iterative reconstruction to keep the dose low.
iDose4 , he says, keeps the natural appearance of the object, despite its use of iterative reconstruction technology (see chest image to left), and keeps up the speed needed to make CT useful in trauma settings.
“The majority of reconstruction images happen in under 60 seconds,” Scott says.
Philips also will present its Ingenuity CT products as a suite, a sort of continuum of increasing sophistication. Scott describes it as “investment protection,” since customers can upgrade in-room.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
January 29th 2025For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.